Graham Speight, Natalie Milner, James Reid, Venu Pullabhatla, Lynne Edhouse, Lyudmila Georgieva
Improved methods of disease status monitoring with detection of low-level variants are essential for research into facilitating early therapeutic interventions and potentially preventing disease recurrence.
A range of methods are used for the detection of measurable residual disease (MRD), with flow cytometry considered the gold standard. Increasingly, molecular methods such as next-generation sequencing (NGS) are being used. Methods differ in applicability, specificity and sensitivity of detecting MRD. Importantly, NGS could provide a solution that would allow the evaluation of many genes and variant types in a single assay.
In this study we aim to evaluate the OGT™ Universal NGS workflow together with a custom SureSeq myPanel™ for suitability with deep sequencing and rare variant detection required for MRD monitoring.
Once you have registered with us for free you will be able to read all our supportive literature, video tutorials and webinars.
